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ABSTRACT
Effects of GABA on Inflammation and Intestinal Barrier Disruption
By Tyrel W. Long
Spring 2022
Gut dysbiosis and intestinal barrier disruption have been linked to multiple sclerosis (MS).
Our previous works show that experimental autoimmune encephalomyelitis (EAE) induction
modifies the gut's microbiota composition, reducing frequencies of gamma-aminobutyric acid
(GABA)-producing bacteria. GABA levels are reduced in the brains and circulation of MS patients.
We engineered Lactococcus lactis with extra copies of gadB (glutamic acid decarboxylase) and
gadC (glutamate/GABA antiporter) to increase GABA levels produced by the bacterium (GAD-L.
lactis). EAE studies showed that the treatment with GAD-L. lactis and not with a L. lactis control
expressing an empty plasmid (P-L. lactis) reduced the severity of the disease. We hypothesized
that the increased levels of GABA produced by GAD-L. lactis would restore the permeability in
the intestinal epithelia of EAE mice and in a monolayer composed of Caco-2 cells exposed to
inflammatory mediators. Intestinal permeability of the in vivo model was measured by the oral
administration of 4-kDa fluorescein isothiocyanate (FITC)-labeled dextran 19 days post-EAE
induction. Results showed increased trend of intestinal integrity when EAE with were treated
with GAD-L. lactis vs. P-L. lactis (not significant). In vitro, Caco-2 cells were plated on tissue culture
trans-well plates creating a monolayer. The Caco-2 cells were exposed to TNF-α, a known barrier
disruptor, and to increasing concentrations of GABA (0 – 10 mM). Transepithelial electrical
resistance (TER) measurements and the flux of (FITC)-labeled dextran were quantified (0-48 hrs).
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Our results showed dose- and time-dependent effects of GABA exposure on monolayer integrity.
Exposure of cells to 0.5 – 1 mM, but not higher, of GABA resulted in significant increases in
monolayer integrity compared with TNF-α controls and unexposed Caco-2 cells over the first (p
= 0.0115) and second hour (p = 0.0006). Continuing work with GAD-L. lactis and the P-L. lactis, in
conjunction with Caco-2 cell monolayers, will help us understand the role GABA has on
permeability.
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Introduction
Multiple sclerosis (MS)
Multiple sclerosis (MS) is one of the most common neurodegenerative diseases affecting
nearly 2.3 million people worldwide. Diagnosis rates vary greatly between regions and
demographics. Prevalence is higher in developed or developing countries (Dobson & Giovannoni,
2019). MS is generally detected in individuals between the ages of 20 and 40, and women are
two times more likely to be affected by the disease than men (Compston & Coles, 2008; Doshi &
Chataway, 2016; Mendibe Bilbao et al., 2019). The affected group's life expectancy is five to ten
years lower than the general population.
Also known as encephalomyelitis disseminata, MS is a demyelinating disease in which the
insulating cover of nerve cells called myelin sheath in the brain and spinal cord is damaged
(Compston & Coles, 2008). MS arises when autoreactive T-cells cause chronic inflammation to
break down the myelin sheath of axons in the central nervous system (CNS) (Basso et al., 2008;
Schumacher, 1957). During initial stages of MS, the degradation of the myelin is sporadic and
produces characteristic “sclerosed plaques” along the CNS (Dobson & Giovannoni, 2019). The
pathology of MS transpires due to T cell-mediated inflammatory response (Lassmann, 1999).
Myelin-specific autoreactive T cells cross the blood-brain barrier (BBB) to enter the CNS and
release proinflammatory cytokines that promote demyelination (Liu et al., 2018). Ultimately the
inflammatory process results in the degradation of the axon and even neuronal death (Basso et
al., 2008; Schumacher, 1957).
As the myelin sheath is damaged, neurons are incapable of effectively transmitting
electrical signals, resulting in various signs and symptoms, including physical, mental, and

debilitating psychiatric effects (Doshi & Chataway, 2016). Double vision, blindness in one eye,
muscle weakness, and problems with sensation or coordination are also possible symptoms
(Kalincik, 2015). MS manifests itself in various ways, with new symptoms appearing in isolated
bouts or over time. Symptoms may go away entirely between attacks, but persistent neurological
issues are common, especially as the condition progresses (Baecher-Allan et al., 2018; Pan et al.,
2018). These include autonomic, visual, motor, and sensory difficulties are among the most
prevalent neurological symptoms and signs in people with MS (Kalincik, 2015), including muscle
spasms, or trouble moving, challenges with coordination and balance; problems with speaking or
swallowing, vision problems, fatigue, acute or chronic pain, and bladder and bowel disorders,
among others (Kalincik, 2015).Additional symptoms include concentration and thinking
difficulties, and emotional issues such as sadness or mood swings are also expected. The
expanded Disability Status Scale (EDSS) is used to quantify disability in MS patients, who also
have an increased tendency to fall. Women with MS who become pregnant have fewer relapses;
nonetheless, the chance of recurrence rises in the first few months after delivery (Wingerchuk &
Carter, 2014). Symptoms can differ drastically from one individual to another.
MS is categorized according to the progressive stages of the disease (Kalincik, 2015). The
most common form of MS is the relapsing-remitting MS (RRMS) and is classified by intervals of
remission followed by relapses where neurological symptoms exacerbate (Lublin, 2014). The
continued demyelination and repair are characterized clinically as RRMS and produce the
identifiable repeating loss of sensory and motor function (Baecher-Allan et al., 2018).
Approximately 85% of the newly diagnosed MS patients are RRMS. Within 10-15 years, 50% of
RRMS patients will emerge into secondary progressive MS (SPMS) with worsening neurological
2

symptoms and few to no remissions. About 15% of the newly diagnosed MS patients with primary
progressive MS (PPMS) have gradually worsened neurological symptoms with slight remission
from the onset of MS (De Angelis et al., 2018).
Identifying the subtypes of MS is vital when deciding on the best treatment plan. RRMS is
characterized by unpredictable relapses followed by periods of months to years of relative
remission with no new signs of disease activity. Deficits that occur during attacks may either
resolve or leave problems, the latter in about 40 % of attacks and being more common the longer
the person has had the disease. 30 to 70 % of persons who experience CIS late develop MS. It is
characterized by progression of disability from onset, with no, or only occasional and minor
remissions and improvements.
Etiology of MS
Although the etiology of MS remains uncertain, many studies suggest that genetic and
environmental factors influence the onset of MS (Ghasemi et al., 2017; Jangi et al., 2016). The
genetic component indicates that some individuals are more vulnerable than others.
Polymorphisms in the human leukocyte antigen (HLA) loci— groups of genes on chromosome 6
that encode the major histocompatibility complex (MHC) molecules MHC class I and MHC class
II, required for antigen presentation to T cell lymphocytes —have been linked to MS. The same
region has also been related to the development of other autoimmune diseases, such as diabetes
type I and systemic lupus erythematosus (Borchers et al., 2014; Maghbooli et al., 2020). A rare
mendelian

genetic

variants

including

KIF5A

p.Ala361Val,

MLC1p.pro92S

and REEP1 c.606 + 43G>T contribute directly to developing the phenotypes of MS (Jia et al.,
2018).
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In addition to genetics, the environment also contributes to the known cause of MS. There
is increasing evidence linking Epstein-Barr virus infection (EBV) to MS (Bjornevik et al., 2022; W.
H. Robinson & Steinman, 2022). The longitudinal analysis provided by Bjornevik et al. looked at
955 military personnel from a cohort of 10 million who were diagnosed with MS. They found that
EBV positive patients had a 32-fold increase in the risk of developing MS (Bjornevik et al., 2022).
Other factors include exposure to human virus type 6, mycoplasma, smoking, pneumonia,
vitamin deficiency, and exposure to UV radiation that may lead to MS development (Ghasemi et
al., 2017).
The geographical location, including latitude, where an individual reside could play a role
in the development of MS. Those who lived in higher latitudes during the primary years have an
increased chance of MS due to a lack of vitamin D (Sintzel et al., 2018). Evidence also found that
people who relocate to a different location of the world before the age of 15 acquire the new
region's risk of MS (Kotzamani et al., 2012). However, if a person migrates beyond the age of 15,
they are still exposed to the risks of their original location (Kotzamani et al., 2012). A relative of
an affected person has an increased risk of developing the condition, with a higher risk among
those who are more closely related. If both parents are affected, their children's risk is ten times
higher than the general population. Several additional potential risk factors, such as food and
hormone consumption, have been investigated, but insufficient evidence links them to the
condition. Genetics and environmental factors such as viral infections have been suggested as
possible reasons.
Experimental Autoimmune Encephalomyelitis (EAE)
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Animal models are an essential part of understanding diseases such as Multiple sclerosis.
Mice are largely used because of the wide availability of transgenic and knockout mice accessible
for specific studies (A. P. Robinson et al., 2014). There are a variety of models used to study the
pathogenesis of diseases effectively. One model that proved successful in studying MS is the
experimental autoimmune encephalomyelitis (EAE). It is effective because it models the
autoimmune-mediated inflammatory demyelination and closely mirrors the pathology and
symptoms of MS (A. P. Robinson et al., 2014). Due to EAE’s substantial utilization and
accessibility, it works well when comparing treatments.
EAE is a condition induced in mice where external immunizations are administered,
resulting in changes in the immunopathological and neuropathological mechanisms to mimic the
pathological features of MS (Constantinescu et al., 2011). EAE can be induced in several ways. In
one method, EAE uses transgenic mice explicitly bred for EAE to spontaneously develop
symptoms (Gold, 2006; Burrows et al., 2019). EAE can also be generated by transplanting the
microbiota of MS patients into germ-free mice (Berer et al., 2017; Cekanaviciute et al., 2017). The
last EAE induction method involves injecting intravenously myelin antigens, including myelin
oligodendrocyte glycoprotein peptide 35-55 (MOG35-55)(Burrows et al., 2019). This causes myelinspecific CD4+ T cells to cross the blood-brain barrier, resulting in inflammation in the CNS,
eventually leading to damage comparable to MS.
The conditions in which EAE develops likewise plays a significant role. For example, mice
given antibiotics before induction to remove the gut microbiota impaired the development of
EAE (J. Ochoa-Repáraz et al., 2010; Javier Ochoa-Repáraz et al., 2009; Yokote et al., 2008). Germ-
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free mice who also did not develop EAE, produced lower levels of proinflammatory cytokines
(Lee et al., 2011). Under the same research, the germ-free mice were given segmented
filamentous bacteria and EAE developed like conventionally colonized animals (Lee et al., 2011).
Additional protective result has included using Bacteroides fragilis that produced polysaccharide
A (J. Ochoa-Repáraz et al., 2010; Wang, Begum-Haque, et al., 2014).
The EAE model is a good indicator of the effects of MS, and it also comes with some
challenges. One of the main concerns with using EAE is the impact of the microbiome on the
development of the immune system (Adamczyk-Sowa et al., 2017). Here at EWU, we worked on
a protocol for analyzing the microbiome of mice that have been induced by EAE (Daberkow et
al., 2021). Data indicated that mice retrieved from different facilities had differences in disease
induction (Daberkow et al., 2021). The results of this protocol have shown the need of having
other methods supporting in vivo studies.
Diagnosis and Current Treatments of MS
MS is typically diagnosed based on the signs and symptoms present and by supporting
medical imaging and laboratory testing. The McDonald criteria, the most widely used
methodology for the diagnosis of MS focuses on clinical, laboratory, and radiologic evidence of
lesions at different times and in distinct regions (Thompson et al., 2018). However, no single test
can provide a definitive diagnosis for MS, and diagnosis may be complex, especially in the early
stages, because the indications and symptoms can be confusing. Additionally, long-term
outcomes are difficult to predict; more prolonged periods of remission are more common in
women, those who have the condition early in life, those who have a relapsing history, and those
who have had few episodes at first (Wingerchuk & Carter, 2014).
6

Magnetic resonance imaging of the brain may show areas of demyelination (Zivadinov &
Leist, 2005). The metal gadolinium can be administered intravenously as a contrast agent to
highlight active plaques and by elimination, demonstrate the existence of lesions not associated
with symptoms at the moment of the evaluation (Zivadinov & Leist, 2005). Central brain lesion
signs have been proposed as a good indicator of MS compared to other conditions causing white
lesions (Cortese et al., 2019). In addition, brain atrophy is seen as an indicator of MS (Zivadinov
& Leist, 2005). Testing of cerebrospinal fluid obtained from a lumbar puncture can provide
evidence of chronic inflammation in the CNS. Cerebrospinal fluid is tested for oligoclonal bands
of IgG on electrophoresis, which are inflammation markers found in 75-85% of people with MS.
Despite the challenges that come with MS diagnosis, early treatment can help lessen the
progression of MS.
Although there is no known cure for MS, a variety of treatments are available to decrease
the progression of MS. The focal point of treatments is to weaken the immune system, therefore
reducing inflammation (Chu et al., 2018; Doshi & Chataway, 2016). Such treatments include
immunotherapeutic drugs that target effector T cells, regulatory T cells, B cells, and cell trafficking
into the CNS (Baecher-Allan et al., 2018). Several therapies have proven beneficial to the
improvement of MS. The primary aims of therapy are returning function after an attack,
preventing new attacks, and preventing disability (Baecher-Allan et al., 2018). Starting
medications is generally recommended in people after the first attack when more than two
lesions are seen on MRI (Baecher-Allan et al., 2018). As with any medical treatment, medications
used in the management of MS have several adverse effects. Academic laboratories and
industries are currently pursuing alternative treatments.
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Probiotics may be an alternative treatment approach against the inflammatory response
of MS. (Colpitts et al., 2017; Dolpady et al., 2016; Tankou et al., 2018). The health benefits of
probiotics have been acknowledged throughout history and appear to impact the immune
system, both experimentally in vivo using animal models and in vitro (Dolpady et al., 2016; Liu et
al., 2018). Probiotics may consist of one or various microbial species. Examples of some bacteria
used in probiotic formulations are members of the family Bifidobacteriaceae (B. longum, B.
infantis, and B. breve), Lactobacillaceae (L. acidophilus, L. paracasei, L. delbrueckii subsp.
Bulgaricus, and L. plantarum), or Streptococcus thermophile. These species of bacteria are
considered commensal (so would they be mutualistic) bacteria and play a positive role in the
individual's health. Other bacteria might be directly involved in the pathogenesis of MS (Hedblom
et al., 2018). Many of these mechanisms are still unknown. For example, the bacterial family of
Verrucomicrobiaceae has an unknown function in autoimmunity (Colpitts et al., 2017). Future
studies will be needed to fully comprehend the functions of bacteria in the gut.
Furthermore, individuals with MS demonstrated a notable change in gut microbial
abundance compared to healthy individuals. This indicates that there is communication between
the host and the gut microbiota (Javier Ochoa-Repáraz & Kasper, 2018). The bi-directional
association between microbiota and those with MS can be shown in the role microbiota has with
the body's immune cells. Altering the gut microbiota by using probiotics can affect the severity
of MS.
Inflammation as a mediator of CNS demyelination
Apart from demyelination, inflammation is another symptom of MS. T cells, thymusderived lymphocytes that play a crucial part in the body's defenses, are in part responsible for
8

the inflammatory process (Khaibullin et al., 2017). Inflammation is a necessary response to
microbial infections and tissue damage in the short run. It is the body's natural healing system in
which the immune system defends the body from foreigners. The body reacts to harmful stimuli
like pathogens, damaged cells, toxic compounds, or irradiation (Chen et al., 2018). The challenge
arises when autoimmune diseases like MS emerge from the immune cells like helper T cells (Th),
ultimately damaging the host (Kaskow & Baecher-Allan, 2018).
The pathology of MS transpires due to Th cell-mediated inflammatory response
(Lassmann, 1999). T cells play a critical role in managing the immune response and pathogenesis
of MS (Kaskow & Baecher-Allan, 2018). When an antigen is presented by antigen-presenting cells
to antigen-specific T-cell receptors (TCRs), the T cell bearing the antigen-specific TCR is activated.
Activation results in clonal expansion and differentiation into T cell subsets with the ability to
respond differently depending on the nature of the insult. Differentiation into different subsets
that include Th1, Th2, Th17, Tregs, and T follicular helper cells is regulated by polarizing cytokines.
Each of these effector T cell subsets produces different cytokines, including inflammatory
cytokines that will further promote inflammation and damage the myelin sheath (MacLeod &
Wetzler, 2007; Reynolds et al., 2012).
Inflammatory cytokines associated with MS include IL-6, TNF-α, IL-1b, IL-17, and IFN-γ
[18]. IL-1β is produced by macrophages and promotes differentiation of T cells into Th17 cells via
the STAT3 pathway, promoting and aggravating the CNS's inflammatory environment (Allam et
al., 2018; Lin & Edelson, 2017). Th17 cells promote and aggravate the CNS's inflammatory
environment (Allam et al., 2018; Lin & Edelson, 2017). Th17 cells found in the CNS of EAE mice
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have been found to send out cytokines including IL-17 that recruit myeloid cells that perpetuate
an inflammatory cascade (Rostami & Ciric, 2013).
Another cytokine is tumor necrosis factor (TNF-α). TNF-α is produced by macrophages,
natural killer cells, and Th1 cells. Its primary role is to regulate immune cells (Carswell et al.,
1975). In the gastrointestinal tract, TNF-α exacerbates inflammation that ultimately changes the
gene expression in tight epithelial junction proteins (Roulis et al., 2011). The intracellular
mechanism behind this process is still unclear (T. Y. Ma et al., 2005), but it has been described
that intestinal epithelial cells express the receptor for TNF-α, and that TNF-α interaction with the
receptor can modulate the expression of tight junction proteins (T. Y. Ma et al., 2004). A decrease
in tight junction protein expression is believed to be correlated with the progression of many
autoimmune disorders (Allam et al., 2018; H. Di Ma et al., 2018). The impact of the changes of
tight junction protein expression on MS is described in further detail below.
The gastrointestinal tract and multiple sclerosis
The gastrointestinal (GI) tract is a muscular tube covered in mucus and an epithelium
(Dieterich et al., 2018). The gut-associated lymphoid tissue (GALT) is a secondary lymphoid
structures surrounding the GI tract and displays both innate and adaptive immune responses
essential for the control of infections, interactions with the beneficial microbiota, and defenses
against microbe translocation (Brenchley & Douek, 2012). Humans are born with a sterile
gastrointestinal tract colonized by bacteria at birth, although pre-birth colonization through the
placenta has also been proposed with conflicting views (Gil et al., 2020). The hygiene hypothesis
states that the infant's environment and genetics can influence the microbiome and affect the
10

probability of developing childhood and adult diseases (Houghteling & Walker, 2015). Recent
analysis indicates that MS patients' gut microbiota composition decreases potentially beneficial
bacteria (Chu et al., 2018; Cox et al., 2021; Jia et al., 2018).
On the contrary, an increase in proinflammatory bacteria is related to autoimmunity
regulation (Kadowaki et al., 2019). Based on these findings, it has been proposed that an altered
composition of the microbiota can lead to exacerbated inflammation. Under this hypothesis,
intestinal dysbiosis changes in the gut microbiome regulate systemic immune responses by
changing the phenotype, proliferation, and functional capacity of inflammatory or regulatory
cells, eventually leading to neuroinflammation and CNS disease (Pröbstel & Baranzini, 2018).
Individuals with MS demonstrated a notable change in gut microbial abundance compared to
healthy individuals, and this indicates that there is communication between the host and the gut
microbiota (Javier Ochoa-Repáraz & Kasper, 2018).
Leaky gut syndrome
Leaky gut syndrome occurs when inflammation in the GI tract causes tight junctions found in the
intestinal epithelia to loosen, allowing bacterial translocation (Anders et al., 2013). The
translocation of gut microbes or microbial products to the lamina propria, tissue underneath the
gut epithelium, may activate inflammatory responses locally and systemically. Systemic
inflammation, characterized by exacerbated production of proinflammatory cytokines, could
cause both T cell immune imbalance and dysfunction and increased bacterial translocation
(Andersen et al., 2017). TNF-α, increased in CNS and circulation in EAE mice and MS patients, can
disrupt an in vitro monolayer of intestinal epithelial cells (Watari et al., 2017). Intestinal barrier
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disruption can cause bacterial translocation, resulting in various complications for those with MS
due to increased inflammation. Leaky gut caused by inflammation could be considered a pathway
that bacteria use to get past the barrier provided by the epithelial layer, but moreover, it could
contribute to the expansion of the pathogenic effects of inflammation in MS (Kinashi & Hase,
2021; Nouri et al., 2014)
γ-aminobutyric acid (GABA)
Anti-inflammatory cytokines that downregulate the impact of proinflammatory responses may
play a positive role in stopping bacterial translocation and decreasing permeability in the
epithelial cells. Other host factors, such as neurotransmitters, could play a similar role. Gammaaminobutyric acid (GABA) is a neurotransmitter found in the CNS and produced in the gut by
bacterial members of the microbiota. GABAergic systems are composed of four primary parts:
the GABA-A receptors, the GABA-B receptor, the GABA transporters, and the enzymes that make
or degrade GABA (Jin et al., 2013). GABA transporters, also known as GAT, help regulate GABA
concentrations and artificial GAT has been used to help change GABA concentrations (Guastella
et al., 1990).
There are many ways in which GABA helps with the regulation of inflammation. It was found in
cultured CD4+ T cells, a concentration-dependent amount of GABA regulated the secretion of 37
cytokines involved with inflammation (Bhandage et al., 2018). Another study looking at a mouse
model of rheumatoid arthritis found that the T cells of the mice treated with GABA had a reduced
proliferative response and a decrease in inflammation (Tian et al., 2011). Additionally, GABAergic
compounds were found to have a protective effect with EAE by reducing proinflammatory
cytokines, including IL12 and INFγ (Bhat et al., 2010).
12

During neuroinflammation, GABA transport is linked with decreased function (Paul et al.,
2014). One area not thoroughly studied is GABA's role in controlling gastrointestinal function
(Auteri et al., 2015). It is proposed that GABA affects the extracellular space in the gut and
prevents pathogenetic T lymphocytes from causing inflammation (Bjurstöm et al., 2008). Many
different bacteria also produce GABA in the GI tract. Lactococcus lactis is a gram-positive
bacterium with a distinct pathway called the GAD pathway, which produces GABA (Anders et al.,
2013). GABAergic agents used by researchers showed decreased cytokine production of
proinflammatory cytokines (Reynolds et al., 2012; Wang, Telesford, et al., 2014). For those
suffering from MS, there appears to be a correlation between GABA concentrations and
inflammation (De Stefano & Giorgio, 2015).
Previous studies highlighted the benefits of GABAergic agents (Wang, Telesford, et al., 2014)
displaying that TNF-α can increase monolayer permeability (Watari et al., 2017). Therefore, this
study will culture Caco-2 cells, a commercially available immortal human intestinal cell line, and
insert them into Transwell plates, creating a monolayer. The monolayer will then be exposed to
TNF-α and gut contents of various EAE mice to observe the permeability effects of TNF-α and
GABA.

In vitro studies applicable to MS research
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Several methods can be used to study the effects of MS, including in vivo (EAE model,
described previously) in vitro, and ex vivo. There is no "one size fits all" method, and each
method has its advantages and disadvantages. Despite the differences, each method can be
useful in explaining various parts of the etiology of MS.
Numerous in vitro models are used for the study of specific processes associated with
human diseases, including those that impact the CNS (Gogolla et al., 2006). However, due to
the complexity of the pathology of MS in vitro models have been explored less (Ponz-Sarvise et
al., 2020; Schlachetzki et al., 2013). Emerging studies have tried to create in vitro methods
primarily in the way of trying to replicate neuronal tissue. Ex vivo studies have been performed
where slice cultures of the brain and spinal cords were used to observe the methylation process
(Zhang et al., 2011). The slides were subsequently used in vitro to find the methylation
mechanism in MS (Birgbauer et al., 2004). The study of stem cells is also an emerging strategy
for exploring MS. Neuronal cells can be cultured from fibroblasts and used in vitro (Hu et al.,
2015). Because MS is a neurological disease, it should be no surprise that there is an abundance
of studies completed on the CNS (Birgbauer et al., 2004; Zhang et al., 2011). The importance of
gut microbiota translocation has been emphasized. However, few studies failed to clearly
demonstrate the mechanism behind translocation within MS.
In vitro methods have previously been used to demonstrate the translocation of the
epithelia (Grothaus et al., 2018; Mir et al., 2016). The creation of a monolayer can aid in
determining the translation of epithelia in MS patients (T. Y. Ma et al., 2004). Creating the
monolayer requires culturing Caco-2 epithelial cells (immortal line of cells derived from human
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colorectal adenocarcinoma cells) into a single layer that is interconnected. The monolayer
replicates the function of the GI tract by creating a barrier of interconnected cells (T. Y. Ma et
al., 2004; Mattar et al., 2001). Using a monolayer is a valid in vitro model to evaluate specific in
vivo parameters. The monolayer cells are grown using appropriate media and an assay to test
their integrity. To measure the monolayer's integrity, the Transepithelial Electrical Resistance
(TER) can be used. TER is quantified by placing one electrode on the top of the monolayer and
another electrode underneath the monolayer (Srinivasan et al., 2015). An electric current will
pass through the monolayer, where the integrity of the barrier can be quantitatively measured
(Srinivasan et al., 2015). Using an epithelial monolayer in vitro model, even considering the
simplicity of the method and its limitations when considering the complexity of a human
condition, might help understand some specific aspects of bacterial translocation in MS.
Changes in the gut microbiota have been observed in individuals with MS. Gut
microbiota tends to play a leading role in an individual's health. Bacterial translocation has been
demonstrated to cause various health concerns. The entire functions of bacteria in the gut are
still relatively unknown. There are inflammatory and anti-inflammatory molecules that play a
key role in bacterial translocation, and this has been observed mainly by the effects shown in
EAE mice. It will be necessary to perform studies in vivo and perform in vitro work. Creating a
monolayer will be essential for studying the role of MS pathogenesis. Using inflammatory
mediators associated with leaky gut to disrupt the integrity of the cell monolayer is an
alternative approach to animal models to address specific questions regarding inflammation
observed in the MS intestinal microenvironment and leaky gut. Furthermore, establishing an in
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vitro model of leaky gut will facilitate the exploration of new treatment approaches against
intestinal dysfunction and systemic inflammation.
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Research Hypothesis
Hypothesis #1
The addition of GABA to a caco-2 cell monolayer will result in a decrease in permeability
compared to an untreated cell monolayer, as measured by trans epithelial resistance and FITC
dextran.
Hypothesis #2
Giving the Caco-2 cell monolayer a GABA producing probiotic will replicate the results found by
the addition of pure concentrations of GABA and decrease the permeability of the monolayer
compared to an untreated cell monolayer.
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Materials and Methods
Cell culture
Caco-2 cells are an immortal line of cells derived from human colorectal adenocarcinoma
cells. It models the intestinal epithelial barrier by spontaneously differentiating once confluent
and includes the formation of tight junction proteins. The Caco-2 (HTB-37) cells were obtained
from the American Type Culture Collection (Rockville, MD, USA), and cultured in a growth media
composed of Eagle's minimum essential medium (Nissui, Japan) with 10% fetal bovine serum
(FBS) and 0.01 % penicillin and streptomycin. Caco-2 cells were incubated under 5% CO2 at 37 ◦C.
When the caco-2 cells reach 80% confluency, cells were subcultured using trypsin and growth
media to appropriate seeding concentrations, as shown below.
Generation of a Caco-2 cell monolayer
The Caco-2 cells were cultured in 24 Transwell chambers (Corning, NY, USA) at a density
of 6 x 104 for each well (Jin et al., 2013). The total amount of cells required for each plate is 1.5 x
106, which required two confluent petri dishes of the Caco-2 cells. Once the Caco-2 cells were
combined, they were added to the apical chamber with growth media and incubated under 5%
CO2 at 37 ◦C.
Transepithelial electrical resistance
The permeability of the monolayer was measured using transepithelial electrical
resistance (TER). The TER measurements were quantified in Ω•cm2 every day for 16 days using a
Millicell ERS-2 voltammeter (Millicore corporation, Billerica, MA, USA). Experiments continued
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once the TER values plateau between 500 to 800 Ω•cm2. Low TER values are correlated more
permeability and high TER values are correlated less permeability.fs
Disruption of Caco-2 cell monolayer
Disruption of the Caco-2 cell monolayer was performed by the addition of TNF-α. Once the Caco2 cell monolayer plateaus between 500 to 800 Ω•cm2, 10 ng/mL of TNF-α is added to the
basolateral side of the monolayer with 1 mL of growth media. The monolayer was then incubated
under 5% CO2 at 37 ◦C, and the TER measured every 24 hours for two days. A permeable
monolayer was considered when TER measurements dropped below 400 Ω•cm2 (Anders et al.,
2013; Watari et al., 2017)
Lactococcus lactis strains
Wild type and engineered strains of Lactococcus lactis (IL1403) were used for this study (Castillo,
unpublished). The L. lactis (IL1403) was first modified with a pAC plasmid that provided
erythromycin resistance (pAC L. lactis). Genes were then added to the plasmid that encode a
glutamic acid decarboxylase (gadB) and GABA/glutamate antiporter (gadC) under the control of
a constitutive promoter (P8s) (Zhu et al., 2015 and Castillo unpublished). The strains used on the
monolayers included the pAC-L. lactis and GAD-L. lactis (the P8s promoter modified L. lactis). The
bacterial strains were grown at 30◦C without shaking in M17 broth or agar plates (Difco
Laboratories, Detroit, MI) supplemented with 0.5% glucose (GM17) and 5ug/mL erythromycin.
GABA levels for each strain were quantified from cell supernatants from each strain of L. lactis
(WT-L. lactis, pAC-L. lactis, P2-L. lactis, and P5-L. lactis, and P8-L. lactis) at stationary growth
phase using a GABA ELISA kit (Khol, unpublished).
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Animals
Ten-week-old male and female C57BL/6 mice used in this experiment were obtained from
the Jackson Laboratory (The Jackson Laboratory, Inc., Bar Harbor, ME, USA). The mice arrived at
Eastern Washington University at eight weeks old. Over the course of the next two weeks, the
mice were given time to acclimate before being induced at ten weeks. All mice were housed at
Eastern Washington University’s vivarium in wire-top cages. All animals had access to water and
food. All aspects of animal care and well-being followed Eastern Washington University's
Institutional Animal Care and Use Committee’s (IACUC) policies and procedures.
Induction of EAE
The C57BL/6 mice were induced using the Hook KitTM, a commercial EAE induction kit
(Hooke Labs, Lawrence, MA). Per manufacturer's guidelines, mice were induced by flank
subcutaneous injection of an emulsion of 250 µg myelin oligodendrocyte glycoprotein peptide in
complete Freund's adjuvant. That same day and two to four hours later, the mice received
intraperitoneal injections of 100 ng/dose of pertussis toxin provided with the kit.
GAD L. lactis treatment
GAD L. lactis is a modified strain of bacteria that has an increased expression of the GAD gene
and produced GABA at levels higher than the wild-type strain (Castillo, unpublished). Specifically,
the P8 strain produced more GABA (4000 ng/mL) than the vector only control (2100 ng/mL)(Khol,
unpublished) The mice were housed in separated cages forming four groups of 12. For controls,
one group had no treatment and no disease induction (Naïve; Group 1) and one with induced
disease, but no treatment (Group 2 EAE control). The third group was induced with EAE and
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treated with L. lactis-wt (Group 3). The final group was EAE induced and treated modified L. lactis
– GAD (Group 4).
Each mouse was orally gavaged with 5 x 108 CFU/day of their treatment bacteria. CFU/mL
were previously correlated with optical density at 600nm (Kohl and Castillo, unpublished).
Control groups were dosed with a sham sterile GM17+erythromycin medium to control for the
added stress of being gavaged. This will be done five days weekly for 21-day. On the 21st day, the
animals were euthanized to avoid animal loss and sample size reduction due to the disease
progression.
Stool processing and cell culturing
50 mg of fecal material was collected from each mouse, once a week, for a total of 21
days. The fecal material was resuspended in 0.5 mL of phosphate buffered saline (PBS) in a
maltodextrin-trehalose solution and stored at -80 ◦C for future use in microbiome studies (Burz
et al., 2019). In addition, the supernatant from the gut content of treated and untreated EAE
mice were stored at -80 ◦C, after centrifugation.
Caco-2 cells were exposed to the gut microbiota and fecal content supernatants from
treated and untreated EAE mice. The monolayer was then incubated under 5% CO2 at 37 ◦C, and
the TER was measured every 24 hours for two days.

To determine the effects of the

supernatants, different dilutions of the supernatants were co-cultured with the Caco-2 cells. The
supernatants were diluted 1:5, 1:10, 1:20, and 1:40 (v/v) with growth media. After the Caco-2
cell monolayer was grown for seven days, 0.2 mL of the diluted supernatant samples were added
to the apical chamber of the monolayer. The monolayer was then given the diluted supernatant
samples and observed for 48 hours (Geirnaert et al., 2017).
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After the Caco-2 cell monolayers were exposed to the microbiome of untreated and
treated EAE mice, TNF- α or sterile PBS was added for 48 hours as described before. After 48
hours, the cells were washed with PBS. 10 μL of the supernatant was added to the apical side of
the monolayer along with 0.5 mL of growth media (Bhat et al., 2010). The basolateral chamber
received 1 mL of growth media.
4-kDa fluorescein isothiocyanate (FITC)-labeled dextran
An additional permeability test was performed after the addition of the gut contents of
the mice. A fluorescent probe called 4-kDa fluorescein isothiocyanate (FITC)-labeled dextran was
used. The protocol for FITC-labeled dextran starts with the washing of the upper and lower
compartment of the Transwell chambers with Hanks' Balanced Salt solution (HBSS). An additional
1 mL of HBSS was added to the basolateral side of the monolayer, and 0.5 mL of FITC-labeled
dextran (1 mg/mL in HBSS) was added to the apical side of the monolayer. The Transwell plate
was incubated under 5% CO2 at 37 ◦C for 15 minutes. Protecting the samples from light, the
transwell will be transferred to a clear bottom black-walled microplate assessed using a plate
reader with 485 nm excitation and 520 nm emission.
Statistical analysis
All were analyzed using GraphPad Prism (GraphPad Inc., La Jolla California, USA). All
permeability measurements were analyzed by a two-way ANOVA followed by a multiple
comparisons test. A statistical significance of p<0.05 was used for all tests.

Results
Quantification of in vitro epithelial cell integrity
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The generation of a monolayer starts with properly culturing cells that will adhere to one another.
The cells chosen for this experiment were human colorectal adenocarcinoma cells (Caco-2). We
first investigated how these cells grew in a transwell plate for 16 days. A gradual increase in TER
measurements was observed during the allotted time, indicating continued growth (Figure 1A).
Two different concentrations of TNF-α, 10 ng/mL and 20 ng/mL, were added to the transwell
plate and compared to non-treated controls (Figure 1B). The addition of TNF-α was intended to
increase the permeability of the monolayer. We observed a significant treatment effect (P < 0.05)
on the TER measurements over both a 24 and 48 hour period (10 ng/mL n=4, 20 ng/mL n=4)
(Figure 1B).
Effects of GABA on epithelial cell integrity
After correctly establishing the proper protocol for generating a monolayer, the next step was to
determine the amount of GABA concentration required to maintain integrity of cell monolayers
treated with TNF-a. This was conducted by completing three experiments where each transwell
of monolayers (n=4) was treated with various GABA concentrations and 10 ng/mL TNF-α to
compare with nontreated controls. All three experiments (n=4) showed no significant differences
in TER measurements when dosed with any concentration of GABA. Monolayer 2 (Figure 2A) (n=
3, 1 mM, 10 mM) showed the opposite results, where permeability significantly increased at both
the 24 and 48-hour mark. The experiment was repeated for monolayers three (Figure 2B) and
four (Figure 2C)(n= 3, 1 μM, 10 μM) to affirm the results. These two monolayers again with the
same concentrations of GABA resulted in a decrease in TER, indicating an increase in
permeability.
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After some consideration, it was decided the effects of GABA might occur within the first
hours of treatment and at lower concentrations. We decided to conduct additional trials and
measure treatment effects at hours 1, 2, 3, 12, 24, and 48. Monolayer 5 (1 mM, 500 μM, 100 μM,
10 μM) showed an increase in TER during the first 3 hours for the 1 mM and 500 μM GABA
concentration (Figure 3A). We wanted to further confirm the difference in permeability by using
the FITC-dextran test. The results indicated lower concentrations of FITC-dextran in the GABA
treated wells compared to the non-treated control. (Figure 3B).
Next, we compared higher concentrations of GABA with the 1 mM and 500 μM amounts.
Monolayer 7 (n=4; 10 mM, 5 mM, 1 mM and 500 μM) was observed for three hours, where
previous results indicated the highest increase in TER with treatment. There was a significant
difference between the 1 mM (P=0.0072) and 500 μM (P=0.0099) amounts compared to controls
and other treatments within the first hour (Figure 5A). FITC-dextran was then administered and
again showed treated groups had lower concentrations when compared to the control wells
(Figure 5B). Monolayer 8 (n=4; 10 mM, 5 mM, 1 mM, and 500 μM) was performed at the same
time as Monolayer 7 with the intent of having the same concentrations observed for 48 hours.
This again showed a significant increase in TER for GABA concentrations 500 μM (P=0.0346)
(Figure 6).

Effects of L. lactis and GAD L. lactis
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With the proper concentrations of GABA known from previous ELISA results (Khol,
unpublished), we wanted to examine how monolayers treated the stool of EAE mice, EAE mice
given pAC, and EAE mice given GAD L. lactis that produces high amounts of GABA would react.
Monolayer 6 (Figure 4) (n=4) was generated, and stool samples were homogenized with growth
media and added directly to the monolayer. We observed no significant increase in TER.
Additionally, there was a big drop in TER after 24 hours, suggesting Caco-2 cell death (figure 4).
Following Monolayer 6, a direct addition of the pAC L. lactis (empty plasmid control) and
P8 GAD-L were used rather than stool. Monolayer 9 (n=6) was established and exposed to TNFa. We observed a significant difference in TER between the P8 and the pAC control (P < 0.0001),
and TNF-α (P=0.0259) after 24 hours (Figure 7A). The treatment was repeated for Monolayer 10
(n=6) and had results comparable to monolayer 9 except for hour 48, where there was a
significant drop in TER (Figure 7B).
In Vivo FITC-Dextran
The results from the in vitro experiments prompted further studies testing the
permutability of mice treated with GAD L. lactis. We administered the P8 (GAD L. lactis) that
produces high amounts of GABA and the control (pAC L. lactis) to C57BL/6 mice (n=10) over a 23
day period. This experiment aimed to determine whether leaky gut would be observed in vivo:
in those animals, with increased intestinal permeability FITC-dextran detected in serum would
be higher than in animals with unaffected intestinal permeability, due to lack of dextran
translocation. The FITC-dextran treatments were given to the C57BL/6 mice on the final day via
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oral gavage. We collected the serum and observed some fluorescence, however, there was no
significance between the P8, P, and controls (Figure 8).
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Discussion
Multiple sclerosis is a neurodegenerative disease that targets the CNS. Although there is no
definitive cause of MS, it was proposed that genetics, viral infection, or other environmental
factors increase the risk of disease. Despite the advantages made towards the pathology and
etiology of MS, there is no cure. Many avenues of study are underway and are essential in dealing
with the progression of MS. The symptoms noted include gastrointestinal challenges including
leaky gut syndrome. Leaky gut syndrome results from an increase in the permeability of the
intestinal epithelial barrier that leads to subsequent bacterial translocation. It was hypothesized
that leaky gut exacerbates the severity and progression of MS. Recent findings have uncovered
lower levels of GABA in the CNS and gut of MS patients. It is believed that changes in the gut
microbiota will aid in modulating the immune system and metabolic pathways, including GABA
production. The purpose of this study was to test the effects of GABA on a monolayer created
from Caco-2 cells to generate a leaky gut model in vitro.
To study the effects of GABA, we had to establish if a monolayer created from Caco-2 cells could
be a viable model to test inflammation and permeability. In addition to replicating previous
studies (Ye et al., 2006), the monolayer with Caco-2 cells was grown and treated with the known
proinflammatory cytokine TNF-α. The first monolayer demonstrated a significant decrease in the
transepithelial resistance (TER) for the 10 ng/mL (n=4, p=0.0101) and 20 ng/mL (n=4, p=0.0171)
doses of TNF-α. This was comparable to the results found in previous studies.
The first step following the successful creation of a monolayer included the addition of GABA to
the monolayer to determine the effects. Three of the six monolayers (monolayers 2, 3, and 4)
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treated with GABA appeared to either have no effect or significantly increase permeability. We
considered that the duration of exposure and GABA concentrations would affect the validity of
the model. The uptake of too much GABA across the membrane of the Caco-2 cellscould have
resulted in cell death leading to the decrease of TER observed. We proposed obtaining TER
measurements during shorter times (hours versus days), and titrated down the concentrations
of GABA used.
In Monolayer 5, we observed an increase in TER during the first three hours of treatment with
concentrations of 1 mM and 500 μM (n=4). This trend was also observed in the FITC-dextran
results. These results suggested specific concentrations of GABA have time-dependent benefits
to intestinal epithelia. This was confirmed in monolayer 7 (n=4) and monolayer 8 (n=4), where at
3 hours, statistically significant results between the control and 1 mM and 500 μM concentrations
of GABA were observed. Although the results were encouraging, we consider that using a simple
monolayer system only composed of Caco-2 cells exposed to GABA might not translate well to
living tissue found in an organism.
We next addressed whether treating the cells with a probiotic capable of producing
enhanced levels of GABA would restore the integrity of the monolayer exposed to TNF-α. The
synthesis of GABA by the genetically engineered strains was the first step in validating the
probiotic L. lactis constructs. Previous ELISAs performed by Hannah Khol and our lab were used
to determine the quantity of GABA generated by the strains. Supernatant from strains cultivated
until they saturated the media in their stationary phase was utilized in the first ELISA. We were
able to compare strains to some extent because they were all developed to the same stage, and
while there was a trend toward increased production, there was no statistical significance. The
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colony forming units (CFU) of the initial bacterial samples that were used in the ELISA study were
not obtained. With a standard curve, notwithstanding the positive ELISA result (correlation of
0.9887 and R squared 97.75 percent). GABA levels could not be normalized using CFU per volume
(CFU/ml). The lack of CFU/ml standardization could explain no statistical significance. You might
change the way you talk about.
For the following GABA quantification tests, supernatants from strains grown to an OD600
of 0.2 for the same amount of time and with known CFU levels (based on growth curves
calculated as reported in the methodology section) were used in the ELISA. The prior ELISA kit
used (LDN BA E-2500) expired, and replacement kits from the same vendor failed to perform, in
addition to the existing limitations of our investigation (observations made by our colleagues at
WSU College of Pharmacy). The GABA ELISA characterization was then carried out with a separate
kit from (AVIVA Systems Biology, GABA ELISA Kit OKEH02564). Unfortunately, the kit’s controls
failed to work, and we were unable to confirm the ELISA results, despite a significant difference
between the pAC and P8 L. lactis strains at OD 1.5 in a strain comparison.
The addition of pAC and P8 to a caco-2 cell monolayer had a beneficial effect (restored
monolayer integrity after exposure to TNF-α for the first 24 hours. This could be due to the
changes in GABA production of L. lactis that happens even in wild-type strains depending on the
environment. All the bacteria used to treat the monolayers were taken from their M17 media
and put in a well that contained the eukaryotic cell growth media. As indicated in the results
section, Dr. Castillo’s lab later confirmed the ability of P8 GAD L. lactis to produce increased GABA
levels compared to pAC and WT L. lactis. This introduced a change in the environment that could
have potentially changed gene expression levels and GABA production. It has been found that
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Lactobacillus brevis, a similar commensal bacterium, had changes in expression levels of gadBC
genes depending on environment and growth phase (Lyu et al., 2018). This could imply the
changes in media could negatively impact pAC and P8 GAD L. lactis. Future experiments would
include measuring the expression of gadBC genes of pAC and P8 GAD L. lactis after its addition
to a Caco-2 cell monolayer and seeing if changes in Media and pH negatively impact these
bacteria.
Many challenges arose in this thesis project. The main problem was identifying the suitable
treatment concentrations and timeframe of measurements. We initially followed what was
found in the literature but had to change due to unsuccessful results. This was exacerbated by
the limited amount of transwell plates and supplies available due to shipping issues. This thesis
was able to show the positive effect GABA has on an intestinal epithelial model in the form of a
Caco-2 cell monolayer.
Additionally, we were able to show any addition of commensal bacteria is beneficial in
the first 24 hours of treatment. It was unclear whether this was due to GABA production or other
effects created from L. lactis, like the increased lactic acid production that might also have antiinflammatory effects. Potential future studies would include running more monolayers with
lower concentrations of L. lactis and performing Qt-PCR to examine the expression of tight
junction proteins.
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Figure 1. Percent change from TNF-α treatment to Caco-2 cell monolayer. The percent change
of Caco-2 cell monolayer was treated with 10 ng/mL TNF-α (n=3) and 20 ng/mL TNF-α (N=3).
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5. TER measurements of the first 14 days of Caco-2 cells grown in transwell plates without
treatment. B. Change in TER percent from T=0 reading for TNF-α treatment of 10 ng/mL
(n=4) and 20 ng/mL (n=4) at 24 and 48 hrs
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Figure 2. GABA treatment of Monolayers 2, 3, and 4 does not increase TER measurements in
24 and 48 hours. TER measurements show the change in percent from initial at hours 24 and 48.
A. Percent change in TER for Monolayer 2 with GABA concentrations of 1 mM (n=4), and 10 mM
(n=4). B. Percent change in TER for Monolayer 3 with GABA concentrations of 1 mM (n=4), and
10 mM (n=4). C. Percent change in TER for Monolayer 4 with GABA concentrations of 10 mM
(n=4), and 5 mM (n=4).
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Figure 3. Treatment of GABA increases TER in the first three hours and has lower FITCdextran. Treatment of GABA increases TER in the first three hours and has lower FITC-dextran.
TER and FITC-dextran measurements show a decrease in permeability from GABA treatments of
1 mM (n = 5), 500 μM (n = 5), 100 μM (n = 5), and 10 μM (n = 5) μM. A. Monolayer 5 change in
percent from initial of TER measurements B. FITC-dextran Measurements in total fluorescence.
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Figure 4. Stool treatment does not significantly change permeability. Stool treatment does not
significantly change permeability. Permeability was measured using TER and recorded as
percent from initial. Stool was taken from control mice (n = 3), EAE induced mice (n = 3), Mice
with the oral administration of pAC L. lactis (n = 3), and Mice with the oral administration of P8
L. lactis This was compared to wells that only had Caco-2 cells (n=3) and Caco-2 cells treated
with 10 ng/mL TNF-α (n=3).
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Figure 5. GABA treatment of Monolayer 7 decreases permeability with higher TER and lower
FITC-dextran. GABA treatment decreases Permeability with higher TER and lower FITC-dextran.
TER and FITC-dextran measurements for Monolayer 7 with GABA treatments of 10 mM (n = 4),
5 mM (n = 4), 1 mM (n = 4), and 500 μM (n = 4). A. Changes in percent from initial of Monolayer
7 over a period of 3 hours. B. FITC-dextran measured in total fluorescence.
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Figure 6. GABA treatment of Monolayer 8 increases TER in the first three hours

Percent Change Monolayer 8

Percent from initial

200

Control
TNF-α

150

GABA Concentration 1
(10 mM)

100

GABA Concentration 2 (5
mM)

50

GABA Concentration 3 (1
mM)

0

r 0 ur 1 ur 2 ur 3 ur 6 r 12 r 24 r 48
u
u
u
u
o
o
o
o
o
H
H
H
H
H Ho Ho Ho

GABA Concentration 4
(500 μM

Figure 6. GABA treatment of Monolayer 8 increases TER in the first three hours. TER and FITCdextran measurements for Monolayer 8 with GABA treatments of 10 mM (n = 4), 5 mM (n = 4),
1 mM (n = 4), and 500 μM (n = 4). Changes were recorded in percent from initial of Monolayer
7 over a period of 48 hours.
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Figure 7 Permeability decrease with treatment of probiotics. Permeability decreases with
treatment of probiotics. Monolayers treated with pAC L. lactis (n = 6) and p8 L. lactis (n = 6). A.
Monolayer 9 TER percent from initial measurements over a period of 24 hours B. Monolayer 10
TER percent from initial measurements over a 48 hour period
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Figure 8 In vivo Dextran experiment. In vivo Dextran experiment. Blood serum collected from
control mice (n = 5), EAE induced mice (n = 5), mice with oral treatment of pAC L. lactis (n = 5)
and p8 L. lactis (n = 5). FITC dextran measured in total amount ug/mL
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